Sugi Predict

Sugi Predict / Compounds / SCHEMBL3673300

SCHEMBL3673300

SCHEMBL3673300

Cc1ccccc1-c1cc2cnc(N[C@@H]3CCCN(C(=O)NC(C)C)C3)nc2n([C@@H]2CCOC2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 3/20 0.47
▸ MAPK10 P53779 3/20 0.47
▸ MAPK9 P45984 2/20 0.47
▸ MAPK14 Q16539 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ CCND1 P24385 10/20 0.41
▸ CDK6 Q00534 9/20 0.41
▸ CDK4 P11802 4/20 0.41
▸ CCND3 P30281 2/20 0.41
▸ CDK2 P24941 11/20 0.40
▸ CCNK O75909 2/20 0.40
▸ CCNA2 P20248 2/20 0.40
▸ CDK7 P50613 2/20 0.40
▸ CCNH P51946 2/20 0.40
▸ MNAT1 P51948 2/20 0.40
▸ CDK12 Q9NYV4 2/20 0.40
▸ CCNE1 P24864 9/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668198 1.00 MAPK8 (0.47) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3679814 1.00 MAPK8 (0.47) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3682187 0.96 MAPK8 (0.48) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3673662 0.92 MAPK8 (0.53) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3667704 0.92 MAPK8 (0.53) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3667725 0.92 MAPK8 (0.53) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3672024 0.92 MAPK8 (0.52) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3678919 0.92 MAPK14 (0.46) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3674459 0.92 MAPK14 (0.46) MAPK8MAPK10MAPK9MAPK14LCK
SCHEMBL3673239 0.92 MAPK14 (0.46) MAPK8MAPK10MAPK9MAPK14LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-09-03 — — US claimed
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-01-07 — — US disclosed
EP-2111861-A1 Compositions of phosphodiesterase type IV inhibitors Ranbaxy Laboratories Limited (IN) 2009-10-28 — — EP disclosed
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-09-03 — — US disclosed
US-20090054382-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS PNPO, TPMT, NOD1 MAPK8 1902/4885MAPK10 2069/4885MAPK9 1561/4885
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS PDE4B, PDE4A, PDE3B MAPK8 60/4885MAPK10 98/4885MAPK9 77/4885
US-20090054382-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS PDE4B, PDE4A, PDE3B MAPK8 62/4885MAPK10 99/4885MAPK9 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.